- PharmaDrug Inc. (PHRX) announces that Robert Schwartz has resigned from the board of directors
- Schwartz has 25 years of healthcare sales and marketing experience dealing with pharmaceuticals, diagnostics, medical devices and equipment, and medical communications
- PharmaDrug will appoint current board member David Kideckel to Schwartz position on the company’s audit committee
- Kideckel has over 20 years of combined industry and capital markets experience
- PharmaDrug Inc. (PHRX) is down 16.67 per cent and is trading at $0.05 per share as of 2:45 p.m. EST
PharmaDrug Inc. (PHRX) has announced the resignation of Robert Schwartz from the board of directors.
Schwartz has 25 years of healthcare sales and marketing experience focused on introducing cost-saving account coverage efficiencies.
He dealt with pharmaceuticals, diagnostics, medical devices and equipment, and medical communications.
Effective immediately, PharmaDrug will appoint current board member David Kideckel to Schwartz’s position on the company’s audit committee.
He has over 20 years of related industry and capital markets experience.
Prior to PharmaDrug, he served as Managing Director, Senior Institutional Equity Research Analyst at ATB Capital Markets.
PharmaDrug is a specialty pharmaceutical company focused on natural medicines such as psychedelics, cannabis and naturally derived approved drugs.
PharmaDrug Inc. (PHRX) is down 16.67 per cent and is trading at $0.05 per share as of 2:45 p.m. EST.